BRISBANE, Calif., March 16, 2026 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical firm advancing the following technology platform of focused immunotherapies geared toward neuroinflammatory illnesses that influence practically 10 million folks worldwide, at the moment introduced that it has granted inducement to a brand new non-executive worker below the phrases of the 2022 Employment Inducement Award Plan. The fairness award was accredited on March 12, 2026, in accordance with Nasdaq Itemizing Rule 5635(c)(4).
The brand new non-executive worker obtained an choice to buy 20,000 shares of Annexon widespread inventory. The choice carries a ten-year time period and an train value per share equal to $5.66, which was the closing value of Annexon’s widespread inventory on March 13, 2026, the date of grant, and vests over 4 years, with 25% of the shares underlying the choices vesting on the primary anniversary of the grant date and a further 1/forty eighth of the shares vesting month-to-month thereafter, topic to continued service by means of the relevant vesting dates.
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is advancing the following technology platform of focused immunotherapies for practically 10 million folks worldwide dwelling with critical neuroinflammatory illnesses. Our founding scientific method focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can result in tissue harm and lack of operate in a number of illnesses. Our focused therapies are designed to cease classical complement-driven neuroinflammation at its supply to offer significant purposeful profit and alter the course of illness. Annexon’s mission is to ship game-changing therapies to sufferers in order that they’ll reside their greatest lives. To be taught extra go to annexonbio.com.
Investor Contact:
